Photocure ASA 2024 AR2
The report highlights Photocure's strong financial and operational performance in 2024, achieving a 10% revenue growth in its Hexvix/Cysview franchise and generating NOK 49.2 million in EBITDA. Key milestones included the regulatory approval of Hexvix in China, the launch of a mobile blue light tower initiative in the U.S., and a strategic partnership with Richard Wolf to develop a next-generation flexible blue light cystoscope. On the sustainability front, Photocure continued its commitment as a UN Global Compact participant, conducted a double materiality assessment aligned with ESRS, and reported that 100% of its critical suppliers now possess environmental policies.
Company: Photocure ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: AR2
Pages: 114
Photocure ASA
Annual Report
The report highlights Photocure's strong financial and operational performance in 2024, achieving a 10% revenue growth in its Hexvix/Cysview franchise and generating NOK 49.2 million in EBITDA. Key milestones included the regulatory approval of Hexvix in China, the launch of a mobile blue light tower initiative in the U.S., and a strategic partnership with Richard Wolf to develop a next-generation flexible blue light cystoscope. On the sustainability front, Photocure continued its commitment as a UN Global Compact participant, conducted a double materiality assessment aligned with ESRS, and reported that 100% of its critical suppliers now possess environmental policies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 3:
Women on Board
Women in Management
Workplace Fatalities
Employees